Present data support the use of GLP1-RAs for improving sexual dysfunction, and its underlying CV problems, in obese patients with ED. A combination of TRT and GLP1-RAs can be considered in selected cases. Data on SGLT2is are too limited to draw final conclusions.
Corona et al. (2026) studied this question.